Hematology

Monitoring and Long-Term Health After Transplant

At a Glance

After stem cell transplant, children with Cernunnos-XLF deficiency need lifelong follow-up: immune recovery, vaccines, blood counts, growth and development, cancer risk, hormones, and kidney, lung, and heart health all require individualized monitoring.

A successful hematopoietic stem cell transplant (HSCT) is a milestone that changes the course of Cernunnos-XLF deficiency, but it is the beginning of a new chapter rather than the end of the journey. Because the genetic pathogenic variant remains in every non-blood cell of your child’s body, they require specialized, lifelong monitoring even after their immune system has been replaced ^[1]^[2].

Immune Recovery and Resolution

The primary goal of the transplant is to provide your child with a working immune system.

Immune Reconstitution: It can take several months to a year for the new cells to fully mature. Doctors track T-cell, B-cell, and Natural Killer (NK) cell counts at individualized intervals to ensure recovery ^[3]^[4].
Healing from Infections: Once the new immune system is functional, chronic infections typically improve. However, discontinuation of IVIG or antimicrobial prophylaxis is conditional on proven immune recovery. Your child may eventually be revaccinated with non-live vaccines on a transplant-specific schedule. Live vaccines remain contraindicated unless explicitly cleared by your specialist team ^[5].
Chimerism: Your team will perform “chimerism” tests to see what percentage of the blood cells are from the donor. While 100% full donor chimerism is a target in some conditions, in immunodeficiencies, mixed or lineage-specific chimerism may provide adequate immune function ^[6]^[7].

What Stays the Same

It is important to remember that HSCT only replaces the blood-building cells. The DNA-repair defect in your child’s brain, skin, and bones remains.

Growth and Microcephaly: Research shows that while the immune system gets better, growth failure and microcephaly typically persist after transplant ^[1]. Your child will likely continue on their own unique growth curve and may still need support from developmental therapists or nutritionists ^[1]^[8].
Neurodevelopment: Developmental delays present before the transplant generally do not go away. Continued assessment by a pediatric neurologist or educational specialist is a standard part of long-term care ^[1]^[9].

Persistent Risks and Cancer Surveillance

Because the XLF protein is missing in other tissues, children remain radiosensitive and have health risks that require careful, individualized surveillance.

1. Hematologic Risks (Blood and Marrow)

Even after a transplant, the remaining host cells and transplant stress can lead to blood issues.

MDS and AML: There is a documented risk of developing Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) ^[10]^[2].
Clonal Changes: Doctors may see clonal changes (like monosomy 7) during routine blood or marrow checks. These must be watched closely by a hematologist ^[11]^[2]. Routine Complete Blood Counts (CBCs) guide these decisions.

2. Secondary Malignancies

Beyond blood cancers, the systemic DNA repair defect and transplant conditioning mean there is a theoretical and observed risk of other cancers, such as lymphoma or solid tumors ^[10]^[12]. While some cohorts have not seen these cancers in the first 15 years, lifelong monitoring is necessary ^[1]^[13]. However, screening should NOT mean unnecessary CT radiation; any routine imaging must have a specific clinical rationale.

3. Endocrine and Organ Health

The chemotherapy used during conditioning can have late effects.

Hormones: Your child may face issues with growth hormones, thyroid function, or future fertility ^[14]^[15].
Organ Function: Long-term checks on the kidneys, lungs, and heart are standard for transplant survivors ^[16]^[17].

As your child grows, they will eventually transition to adult specialists who understand DNA-repair disorders. This hand-off is a critical part of ensuring they continue to receive protective monitoring as adults ^[18]^[19].

Common questions in this guide

How long does immune recovery take after a stem cell transplant for Cernunnos-XLF deficiency?

Immune recovery can take several months to a year after transplant. The care team follows T cells, B cells, and natural killer cells, and decides when it is safe to reduce treatments such as IVIG or infection-prevention medicines.

Does a stem cell transplant correct all of the effects of Cernunnos-XLF deficiency?

No. The transplant replaces blood-forming cells and can restore immune function, but the DNA-repair problem remains in other tissues, including the brain, skin, and bones. Growth failure, small head size, and developmental delays may therefore continue after transplant.

What does chimerism mean after transplant?

Chimerism measures how much of the blood comes from the donor compared with the child. The desired result is individualized; some children with immune deficiencies can have adequate immune function with mixed or lineage-specific donor cells rather than complete donor chimerism.

What blood and cancer problems need long-term monitoring after transplant?

Follow-up may include regular blood counts and, when needed, blood or marrow evaluations for clonal changes, myelodysplastic syndrome, or acute myeloid leukemia. The underlying DNA-repair disorder and transplant conditioning may also increase concern about lymphoma or solid tumors, so imaging should be ordered for a clear clinical reason rather than routinely using CT scans.

When can my child receive vaccines after transplant?

Non-live vaccines may be restarted on a transplant-specific schedule once the care team confirms sufficient immune recovery. Live vaccines remain unsafe unless the child’s specialist team specifically clears them.

Which long-term health problems should be checked as my child grows?

Follow-up commonly includes growth and development, thyroid and growth-hormone function, future fertility, and kidney, lung, and heart health. A written survivorship plan can help coordinate the transplant team, hematologist, developmental specialists, and adult specialists during transition.

Get notified when new evidence is published on Cernunnos-XLF deficiency.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References (19)

1
Outcome of hematopoietic cell transplantation for DNA double-strand break repair disorders.
Slack J, Albert MH, Balashov D, et al.
The Journal of allergy and clinical immunology 2018; (141(1)):322-328.e10 doi:10.1016/j.jaci.2017.02.036.
PMID: 28392333
2
NHEJ1 Splice Variants Associated With Bone Marrow Failure and Hematologic Malignancy.
Weinstock NI, Applegate C, Peng L, et al.
Pediatric blood & cancer 2025; (72(9)):e31884 doi:10.1002/pbc.31884.
PMID: 40580024
3
Immune recovery and the role of recent thymic emigrated T lymphocytes after pediatric hematopoietic stem cell transplantation.
Justus JLP, Beltrame MP, de Azambuja AP, et al.
Cytotherapy 2024; (26(9)):980-987 doi:10.1016/j.jcyt.2024.04.073.
PMID: 38762804
4
Relevance of Recent Thymic Emigrants Following Allogeneic Hematopoietic Cell Transplantation for Pediatric Patients with Inborn Errors of Immunity.
Drozdov D, Luo X, Marsh RA, et al.
Transplantation and cellular therapy 2025; (31(4)):265.e1-265.e12 doi:10.1016/j.jtct.2025.02.003.
PMID: 39923938
5
Hematopoietic stem cell transplantation for primary immunodeficiency.
Alsaati N, Grier A, Ochfeld E, et al.
Allergy and asthma proceedings 2024; (45(5)):371-383 doi:10.2500/aap.2024.45.240069.
PMID: 39294909
6
Evaluation of Chimerism Dynamics after Allogeneic Hematopoietic Stem Cell Transplantation in Children with Nonmalignant Diseases.
Faraci M, Bagnasco F, Leoni M, et al.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2018; (24(5)):1088-1093 doi:10.1016/j.bbmt.2017.12.801.
PMID: 29292059
7
[Clinical and immunological evaluation of patients with inborn errors of immunity after hematopoietic cell transplantation].
Llarens A, Cabanillas D, Tejada MP, et al.
Archivos argentinos de pediatria 2026; (124(5)):e202611024 doi:10.5546/aap.2026-11024.
PMID: 42189513
8
Late effects after allogeneic hematopoietic stem cell transplantation in patients with primary immunodeficiency.
Grubliauskaitė G, Mulevičienė A, Rascon J
Frontiers in immunology 2026; (17()):1752700 doi:10.3389/fimmu.2026.1752700.
PMID: 42459651
9
Late Effects Surveillance Recommendations among Survivors of Childhood Hematopoietic Cell Transplantation: A Children's Oncology Group Report.
Chow EJ, Anderson L, Baker KS, et al.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2016; (22(5)):782-95.
PMID: 26802323
10
Genetic variants in NHEJ1 and related DNA repair disorders: insights into phenotypic heterogeneity and links to hypoplastic myelodysplastic syndromes and familial hematological malignancies susceptibility.
Elbadry MI, Abdelkreem E, Tawfeek A, et al.
Annals of hematology 2025; (104(3)):1633-1653 doi:10.1007/s00277-025-06257-6.
PMID: 40047910
11
Case Report: Refractory Cytopenia With a Switch From a Transient Monosomy 7 to a Disease-Ameliorating del(20q) in a NHEJ1-Deficient Long-term Survivor.
Poyer F, Jimenez Heredia R, Novak W, et al.
Frontiers in immunology 2022; (13()):869047 doi:10.3389/fimmu.2022.869047.
PMID: 35812385
12
Hematopoietic Stem Cell Transplantation for DNA Double Strand Breakage Repair Disorders.
Wolska-Kuśnierz B, Gennery AR
Frontiers in pediatrics 2019; (7()):557 doi:10.3389/fped.2019.00557.
PMID: 32010653
13
Update on DNA-Double Strand Break Repair Defects in Combined Primary Immunodeficiency.
Slatter MA, Gennery AR
Current allergy and asthma reports 2020; (20(10)):57 doi:10.1007/s11882-020-00955-z.
PMID: 32648006
14
ENDOCRINE COMPLICATIONS IN PATIENTS WITH GVHD.
Akirov A, Sawka AM, Ben-Barouch S, et al.
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2019; (25(5)):485-490 doi:10.4158/EP-2018-0529.
PMID: 30657358
15
Late endocrine effects after hematopoietic stem cell transplantation in children with nonmalignant diseases.
de Kloet LC, Bense JE, van der Stoep MYEC, et al.
Bone marrow transplantation 2022; (57(10)):1564-1572 doi:10.1038/s41409-022-01755-x.
PMID: 35840745
16
Chronic kidney disease ten years after pediatric allogeneic hematopoietic stem cell transplantation.
Lugthart G, Jordans CCE, de Pagter APJ, et al.
Kidney international 2021; (100(4)):906-914 doi:10.1016/j.kint.2021.05.030.
PMID: 34102218
17
Kidney and Blood Pressure Outcomes in Children Surviving at Least 6 Months after Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis.
Sun C, Masood S, Kiyingi JJ, et al.
Transplantation and cellular therapy 2026; (32(9)):1146-1174 doi:10.1016/j.jtct.2026.01.028.
PMID: 41771369
18
Retrospective, Landmark Analysis of Long-term Adult Morbidity Following Allogeneic HSCT for Inborn Errors of Immunity in Infancy and Childhood.
Day JW, Elfeky R, Nicholson B, et al.
Journal of clinical immunology 2022; (42(6)):1230-1243 doi:10.1007/s10875-022-01278-6.
PMID: 35579633
19
Quality of Life and Social and Psychological Outcomes in Adulthood Following Allogeneic HSCT in Childhood for Inborn Errors of Immunity.
Nicholson B, Goodman R, Day J, et al.
Journal of clinical immunology 2022; (42(7)):1451-1460 doi:10.1007/s10875-022-01286-6.
PMID: 35723794

This page is for informational purposes only and does not replace medical advice. Long-term monitoring after HSCT for Cernunnos-XLF deficiency should be individualized by your child’s transplant team, hematologist, and other specialists.